The FDA Granted These Three Companies Orphan Drug Designations in One Day
May 12 was a big day for advancing rare disease treatment as the FDA granted Orphan Drug Designation to Stealth BioTherapeutics, Neurocrine Biosciences, and Editas Medicine. Stealth BioTherapeutics aims to treat Duchenne muscular dystrophy, Neurocrine Biosciences is focused on chorea associated with Huntington’s disease, and Editas Medicine on beta thalassemia, a rare blood disorder.
It's free! Log in now to read
LATEST
Neurosurgery Now: NVIDIA’s Holoscan AI Brings Real-Time 3D Vision to Enhance Surgical Precision at 2025 GTC
2025-03-18
NVIDIA GTC 2025: BioMap’s xTrimo — The AI Model That’s Changing Biotech and Drug Discovery
2025-03-18